Author

Yuewei Xu

Imperial College LondonPrimary ORCID profile (0000-0002-5886-7884 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Yuewei XuiD1 paper · Imperial College London

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Anke M. NijhuisiD· 1 shared Barbara Martins Da CostaiD· 1 shared Chenchen Jin· 1 shared Chiharu WickremesingheiD· 1 shared Evon PooniD· 1 shared Hector C. KeuniD· 1 shared Louis ChesleriD· 1 shared Nikolaos Zourdoumis· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Anke M. NijhuisORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders

Yurui Ma, Evon Poon, Chenchen Jin, Barbara Martins Da Costa, Yuewei Xu, Sadiya Quazi, Nikolaos Zourdoumis, Chiharu Wickremesinghe, Louis Chesler, Hector C. Keun, Anke M. Nijhuis

This paper combines RBM39 degradation and SRPK1 inhibition to disrupt RNA splicing in neuroblastoma, showing synergistic anti-cancer effects in cell lines and a mouse model.

Cell Reports · Jan 1, 2026Peer-reviewedCancer Biology